{"entity":{"id":"nct04884360","kind":"trial","name":"D9319C00001- 1L OC Mono Global RCT","aka":[],"tldr":"A phase 3 trial of Olaparib in ovarian cancer, run by AstraZeneca, active and no longer recruiting.","summary":"D9319C00001- 1L OC Mono Global RCT is a phase 3 interventional study registered as NCT04884360 by AstraZeneca, with 366 participants enrolled, started 2021-05-31 and due to reach its primary completion in 2026-07-27. Interventions recorded: Olaparib, Matching placebo. Conditions listed: Ovarian Cancer. No results are recorded here; the registry entry is the source.","status":"active","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT04884360","url":"https://clinicaltrials.gov/study/NCT04884360"}],"tags":["ctgov-ingest"],"related":[],"cancers":["ovarian"],"sections":[],"technologies":[],"targets":[],"drugs":["olaparib"],"companies":["astrazeneca"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT04884360","phase":"3","setting":"A Randomised, Double-blind, Placebo-controlled, Phase III Study of Olaparib Maintenance Monotherapy in Participants With BRCA Wild Type Advanced High Grade Serous or Endometrioid Ovarian Cancer Following Response to Standard First-line Platinum-based Chemotherapy (MONO-OLA1)","sponsor":"AstraZeneca","enrolled":366,"outcomes":[]},"route":"/trials/nct04884360/","neighbours":{"cancer":[{"id":"ovarian","kind":"cancer","name":"Ovarian cancer","route":"/cancers/ovarian/"}],"drug":[{"id":"olaparib","kind":"drug","name":"Olaparib","route":"/drugs/olaparib/"}],"company":[{"id":"astrazeneca","kind":"company","name":"AstraZeneca","route":"/companies/astrazeneca/"}]}}